The Use of Model Organisms in Sterilizing Filtration - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Use of Model Organisms in Sterilizing Filtration

Pharmaceutical Technology

There are advantages and disadvantages to using model microorganisms in the validation of sterilizing filtration. Although filtration validation studies may demonstrate the removal of the challenge organisms (whatever they may be), those studies can only imply that any particular filter used to filter a batch of drug product will yield a sterile filtrate. Successfully passing a bubble-point test (1) (or multipoint diffusive-flow integrity test), the results of which have been correlated to successful microbial challenge testing and validation studies, provides additional assurance that a sterile filtrate has been obtained. The filter manufacturer's quality-management system and production-control program further support the validity of the sterilizing filtration process. All three elements must be present to predict the successful outcome of a particular sterile filtration event (2).

Filter suitability

Perhaps the best method of determining whether a filter can yield sterile effluent is to subject the drug product to a proper microbial challenge and to analyze the filtrate for its microorganism content. This method of direct measurement would seem to be the most reliable way of characterizing a filter's sterilizing ability. Even though an individual filter can be characterized by a direct microbial challenge, however, the tested filter may not then be used in a processing operation because it has been contaminated by the test organisms.

In practice, the measurement of a filter's sterilizing capability is derived from a correlation of its degree of bacterial retention with a characterization of its largest pores, essentially in terms of their width. The latter is obtained by means of the bubble-point integrity test method (3). It is necessary to confirm this correlative relationship because to assume it exists could prove a mistake. For instance, two qualities or properties of a filter may so constantly occur together as to be assumed to be correlated. Actually, they may in fact be two independent but parallel events that are not correlated (1). For example, single-point air diffusion rates of a filter measured at 5 psi had formerly been thought to correlate with a bubble point of some 50 psi for that filter, but it was discovered that it was necessary to determine the bubble point by measurements made at the actual bubble-point pressure. It did not necessarily correlate with the extension of the 5 psi single-point air diffusion test reading in all cases. So what had seemed to be a correlation turned out to be a case of parallel events. As a result, the use of single-point diffusive airflows measured at 5 psi was abandoned. In the present instance, extensive examination by many investigators has established the validity of correlating the bubble point with microbial retention (4).

An inherent assumption

Factors affecting pore-size ratings
A filter can be characterized by direct microbial challenge as being capable of producing a sterile effluent. Extrapolating from the properties of the tested filter to other "identical" filters would, however, involve assumptions related to the uniformity of the filters' manufacture. To investigate this aspect of the filtration picture to a statistically meaningful level would involve a large number of correlated studies. Moreover, it might well necessitate the disclosure of proprietary information in a competitive market. This would prove highly impractical. From this one consideration alone, it becomes evident that a fundamental assumption must be made, namely, that the filter manufacturers can be depended upon to control their manufacturing processes so that "identical" filters achieve the same level of retention performance.

Reliance upon the filter manufacturer is one necessary factor in this action. Identifying the requirements does not ensure the attainment of sterile effluent.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here